View more job listings or post a job
Clovis Oncology Translational Medicine Operations Specialist
RAPT Therapeutics Director Drug Metabolism/Pharmacokinetics
Genentech, Inc. Associate Director/ Director, Drug Discovery Outsourcing
PTC Therapeutics Director, Drug Metabolism and Pharmacokinetics (DMPK)
Frontier Medicines Principal Scientist Protein Sciences
Frontier Medicines Principal Scientist/Senior Scientist Biochemistry
Frontier Medicines Director/Associate Director Chemical Biology
Frontier Medicines Principal Scientist Chemical Biology
Frontier Medicines Scientist / Senior Scientist, Computational Chemistry
Frontier Medicines Scientist/Senior Scientist, in vivo pharmacology, Disease Biology
Frontier Medicines Senior R&D Scientific Systems and Software Engineer
Post a job


[Free Online Symposium] The Drug Discovery and Development Journey of Polivy™ (Polatuzumab Vedotin): An Antibody-Drug Conjugate for the Treatment of Diffuse Large B-cell Lymphoma

Speakers: Andy Polson (Discovery Lead), Dale Miles (Clinical Pharmacology Lead), Donglu Zhang (DMPK with regulatory responses): ALL Principal Scientists from Genentech
Organizers: Cyrus Khojasteh, PhD
Date: 2020-11-13
Time: 11:00-13:00 Pacific Time
Registration fee: (USD):
Location: Online via Zoom
Major Sponsor:
Vendor show vendors registered to date:
Registration deadline:2020-11-11  (it will close sooner if the seating cap is reached)

About the Topic

Polatuzumab vedotin (POLIVY) is an antibody-drug conjugate (ADC) that contains a humanized immunoglobulin-G1 (IgG1) anti-human CD79b monoclonal antibody and a potent anti‑mitotic agent, monomethyl auristatin E (MMAE), linked through a protease‑cleavable linker, maleimidocaproyl‑valine‑citrulline‑p‑aminobenzyloxycarbonyl (mc‑vc‑PAB). Polatuzumab vedotin has been recently approved in US, Canada, and European Countries to treat B-cell lymphomas. This symposium covers an overview of POLIVY discovery and development which will include its early discovery and clinical readouts, novel clinic pharmacology strategies, and unique regulatory response strategies. The audience will learn about a successful ADC discovery story and embrace the differences between small molecule and ADC drug development.    

2020-10-29, [Free Online Symposium] No More Undruggables: Unconventional Approaches for Drug Discovery and Design - prodrugs, PROTACS, fragment-based design, directed evolution and beyond
2021-07-29, Development of Inhalation Therapeutics (a joint symposium by AAPS-BADGE / PBSS / Genentech)
©Pharmaceutical & BioScience Society, International; Last Modified: 10/23/2020; Admin Logon
Ads (in random order)
Submit a Text Ad
($250 for 2 months)

Eurofins Discovery Biomarker Services Cytokine Storm Assay for immunosafety profiles, STING Assay for in-depth evaluation of immune impacts; 360+ multiparameter flow cytometry capabilities
BioPharmEquip cGMP isolators, adherent-cell bioreactors, stability, CCIT + HGA, viable air sampler, -80C biorepository walk-ins, vH202
Hypha Discovery Limited Experts in drug metabolite synthesis & purification including CYP, AOX, FMO metabolites as well as O-, N-, acyl- glucuronides, glycosides & sulfates.
Eurofins Discovery On-Demand Take a coffee break with Discovery On-Demand! Mini webinars for remote learning avail 24/7 to accelerate your drug discovery program with confidence.
Eurofins Discovery Phenotypic Services Take a human-centered unbiased approach to drug discovery: Our Phenotypic Center of Excellence features BioMAP®, Biomarker, and OncoPanel™ Services
Alturas Analytics, Inc. Expert GLP & non-GLP LC-MS/MS, GC-MS/MS bioanalytical & PK/TK analysis services of small & large molecules in any matrix. Discovery through phase IV.
Submit a Text Ad